FGFR2: A Protein Involved in Tissue Development as A Drug Target

Target Name: FGFR2

NCBI ID: G2263

FGFR2

FGFR2: A Protein Involved in Tissue Development as A Drug Target

FGFR2 (FGFR2 variant 3) is a protein that is expressed in various tissues, including the skin, heart, and kidneys, and is known for its role in cell signaling. FGFR2 has been identified as a potential drug target and is the focus of ongoing research for the development of new treatments for various diseases.

The FGFR2 protein is a member of the Fairyman-Gilbert gene family, which is known for its role in the development and maintenance of tissues and organs. The FGFR2 gene is located on chromosome 11 and is responsible for the production of a protein that is critical for the development and growth of tissues.

FGFR2 is a protein that is expressed in a variety of tissues, including the skin, heart, and kidneys. It is highly expressed in the skin, where it plays a role in the development and maintenance of hair follicles. FGFR2 is also expressed in the heart, where it is involved in the development and maintenance of heart muscle cells. Additionally, FGFR2 is expressed in the kidneys, where it is involved in the development and maintenance of kidney cells.

FGFR2 has also been shown to be involved in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. For example, studies have shown that high levels of FGFR2 are associated with an increased risk of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

FGFR2 has also been identified as a potential drug target. Researchers have shown that FGFR2 is involved in a variety of signaling pathways that are important for the development and growth of tissues. By targeting FGFR2, researchers believe they may be able to develop new treatments for a variety of diseases.

One approach to targeting FGFR2 is to use small molecules, such as drugs, to inhibit the activity of FGFR2. These drugs can be administered to patients and have been shown to reduce the activity of FGFR2, which can lead to the inhibition of cell signaling pathways that are involved in the development and growth of tissues.

Another approach to targeting FGFR2 is to use antibodies, which are proteins that are designed to recognize and bind to specific molecules on the surface of cells. These antibodies can be used to target FGFR2 and have been shown to reduce the activity of FGFR2 in cells.

Research into FGFR2 is ongoing, and there is a great deal of excitement about the potential of targeting this protein as a drug target. Studies are being conducted to determine the effectiveness of different approaches to target FGFR2, including the use of small molecules and antibodies.

In conclusion, FGFR2 is a protein that is involved in the development and growth of tissues and has been identified as a potential drug target. Further research is being conducted to determine the effectiveness of different approaches to target FGFR2, including the use of small molecules and antibodies.

Protein Name: Fibroblast Growth Factor Receptor 2

Functions: Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation, migration and apoptosis, and in the regulation of embryonic development. Required for normal embryonic patterning, trophoblast function, limb bud development, lung morphogenesis, osteogenesis and skin development. Plays an essential role in the regulation of osteoblast differentiation, proliferation and apoptosis, and is required for normal skeleton development. Promotes cell proliferation in keratinocytes and immature osteoblasts, but promotes apoptosis in differentiated osteoblasts. Phosphorylates PLCG1, FRS2 and PAK4. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. FGFR2 signaling is down-regulated by ubiquitination, internalization and degradation. Mutations that lead to constitutive kinase activation or impair normal FGFR2 maturation, internalization and degradation lead to aberrant signaling. Over-expressed FGFR2 promotes activation of STAT1

The "FGFR2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FGFR2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets